Supplementary Materials



Fig. S1. Effect of atorvastatin on statin-resistant NCI-H322M and statin-sensitive HOP-92 cells

Phase-contrast imaging of NCI-H322M and HOP-92 cells treated with atorvastatin for 24 h. NCI-H322M and HOP-92 cells were treated with 1 and 10 μ M atorvastatin and 0.1 and 1 μ M atorvastatin for 24 h, respectively (vehicle control, 0.1% DMSO). In HOP-92 cells, cellular shrinkage was observed at 1 μ M atorvastatin. Scale bar = 100 μ m.

NCI-H322M



HOP-92





All western blot images are full-length blots of HMGCS1, HMGCR, FDFT1, GGPS1, and GAPDH. Membranes were stripped with western blot stripping buffer (Takara Bio, Shiga, Japan) and probed with other antibodies.



Fig. S3. The mRNA expression levels of *PANK2* and *SOAT1* in statin-resistant DU-145 and statin-sensitive PC-3 cells treated with atorvastatin for 24 h

Real-time PCR analyses of *PANK2* (A and B) and *SOAT1* (C and D) expression in statinresistant DI-145 and statin-sensitive PC-3 cells treated with atorvastatin. Real-time RT-PCR data were normalized to *RPLP1* levels in each sample and expressed as values relative to those of the internal control. The measurement values for each group were compared using Dunnett's test and Student's t-test. Mean \pm standard deviation, n = 3, **P* < 0.05, ***P* < 0.01.

Gene		Primer sequence	Product size
HMGCS1	Forward Reverse	5'- CTCTTGGGATGGACGGTATGC -3' 5'- GCTCCAACTCCACCTGTAGG -3'	90 bp
HMGCR	Forward Reverse	5'- GCCTGGCTCGAAACATCTGAA -3' 5'- CTGACCTGGACTGGAAACGGATA -3'	136 bp
GGPS1	Forward Reverse	5'- CACTTGGGCTCTTTTTCCAA -3' 5'- GCGCAAGATATTCTGCACCT -3'	170 bp
FDFT1	Forward Reverse	5'- GGAAGACCAGCAAGGAGGAA -3' 5'- ACTGCACGGCCAAGTCAATA -3'	110 bp
PANK2	Forward Reverse	5'- GGATCGACTGGGCTCTTACA -3 5'- TTGGAGGTCAGGTACTTCCG -3	213 bp
SOAT1	Forward Reverse	5'- GAAACCGGCTGTCAAAGTCC -3' 5'- AATGGCTTCAATTCCTCTGC -3'	163 bp
RPLP1	Forward Reverse	5'- AGCCGGTGTAAATGTTGAGC -3' 5'- CAGATGAGGCTCCCAATGTT -3'	81 bp

Supplementary Table S1. Primer sets for Real-time RT-PCR